COMPOUNDS AND METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS

Abstract: A short-acting ss-blocking compound of the formula (FORMULA) wherein Ar may be substituted or unsubstituted aromatic, Y may be a straight or branched carbon chain or aralkyl, R may be lower alkyl, lower alkenyl, lower alkynyl, aryl or aralkyl, and x is an integer from 1 abut 3; or a pharmaceutically acceptable salt thereof.

Description: COMPOUNDS ANO METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS Backσrouπd of the Invention The present invention relates to the treatment or prophylaxis of cardiac disorders. More particul rly, the invention relates to a novel method of treatment or prophylaxis of cardiac disorders which comprises administration of 3-adreπergic blocking agents and to compounds useful in such method. • 10 The therapeutic and prophylactic uses of compounds which block sympathetic nervous stimulation of S-adrenergic receptors in the heart, lungs, vascular system and other organs are well documented. Typically, such compounds are administered therapeutically to patients 15 suffering from ischemic heart disease or myocardial infarction for the purpose of reducing heart work, i.e., heart rate and contractile force. Reducing heart work reduces oxygen demand, and may also actually increase oxygen supply. Thus reducing heart work can aid in the pre¬ vention of further tissue damage and can relieve angina pectoris. 0 β -Adrenergic stimulation may also aggravate or cause arrhythmias because of increased levels of catechol amines. Thus 3-blocking agents may be employed to reduce the risks of arrhythmias. 5 Compounds have been discovered which selectively block 3-adreπergic receptors in various organs. Beta receptors in the heart are generally referred to as β j receptors, and those associated with vasodilation and bronchodilation are B ? receptors. Non-selective β -blockers are not preferred for the treatment of cardiac disorders 0 because of their hypertensive action and potention undesirable effects on asthmatic patients. A number of β 1 selective adrenergic blocking agents have been discovered. Smith, L.H., J. Appl. Che . Biotech no!., Z_, 201-212 (1978). Most of such compounds are structural variations of l-amino-3-aryloxy-2-propaπol . 5 Heretofore, the- emphasis in B-blocker research has been to develop compounds which can be administered to cardiac patients over long periods of time. However, often it is desirable in the critical care setting to quickly reduce heart work or improve rhythmicity during a cardiac crisis, e.g., during or shortly after a myocardial infarc- 0 tion. Conventional β-blocking agents can be employed for such treatment, but their duration of action may be much longer than desired by the physician. A _. -blocking agent possessing a long duration of action does not allow precise control of heart work or prompt reversal of the B-blockiπg effect, which may be required in a critical care 5 setting. For instance, if heart output becomes dangerously low, it is desirable to quickly reduce or eliminate β-blocking activity. The lingering activity of available 3 -blocking agents can be counter¬ productive and can greatly complicate the therapeutic decisions required of the physician during such critical care of cardiac 0 patients. Summary of the Invention In accordance with the present invention, disclosed herein is a method for the treatment or prophylaxis of cardiac disorders in a mammal 5 comprising administering to such maπmal a short-acting compound of the formula: OH I Ar-0-CH 2 -CH-CH 2 -N-Y ■C-O-R 0 wherein Y is a straight or branched carbon chain of from 1 to about 10 carbon atoms or aralkyl of from 8 to about 20 carbon atoms; R is lower alkyl, lower alkenyl, lower alkynyl, aryl or aralkyl; x is an integer from 1 to about 3; Ar is unsubstituted aromatic or aromatic substituted __* with lower alkyl, lower al enyl, lower alkynyl, lower alkoxy, halogen, acetamido, amino, πitro, lower alkylamiπo, hydroxy, lower hydroxyal yl , cyano, or a group of the formula OMPI wherein n is an integer from 0 to about 10; or a pharmaceutically acceptable salt thereof. Detailed Description of the Invention In accordance with the present invention, it has been discovered that compounds having an ester function in external amine substituents possess 3-adrenergic blocking activity and have a short duration of action. Such compounds may also contain more than one ester group in the same molecule. the compounds of the present invention are represented by the formula: Y may be a straight or branched carbon chain of from 1 to about 10 carbon atoms, e.g., methyl ene, ethyl ene, propyl ene, 2-ethylhexylene, 1,1-dimethyl ethyl ene, and the like or aralkyl of from 8 to about 20 carbon atoms, such as dialkylene phenyl, e.g., 4-ethylenebenzyl, l-propylene-(4-naphthyl)-2-n-butyl, and the like. R may be lower alkyl of from 1 to about 10 carbon atoms, such as methyl, propyl, t-butyl, 3-propylheptyl, and the like;- lower alkenyl of 'from 2 to about 10 carbon atoms, such as ethenyl, propenyl, 4-ethy1-2- hexenyl, and the like, lower alkynyl of from 2 to about 10 carbon atoms, such as ethynyl, propynyl, 4-ethyl-3-octynyl , and the like; aryl of from 6 to about 10 carbon atoms such as phenyl, 2-tolyl, 2-methoxy- phenyl, naphthyl, and the like or aralkyl, wherein the al yl portion contains from 1 to about 10 carbon atoms and the aryl portion contains from 6 to about 10 carbon atoms, such as benzyl, phenethyl, 1-naphthyl- propyl, 3,4-dimethoxyphenethyl, and the like. The amine substituent may conta n one or more ester groups, thus x is an integer from 1 to about 3 provided that when x is greater than 1, different occurrances of the-COOR group may be the same or different. Ar represents substituted or unsubstituted aromatic, i ncl udi ng monocyclic, polycyclic, and heterocycli c ri ng systems. Aromatic sub- stituents i ncl ude l ower arkyl , of from 1 to about 10 carbon atoms , l ower al kenyl , of from 2 to about 10 carbon atoms, lower alkynyl , of from 2 to about 10 carbon atoms, l ower al koxy of from 1 to about 10 carbon atoms , halogen, acetamido, a ino, πitro, lower alkyl amino, of from 1 to about 10 carbon atoms , hydroxy, l ower hydroxyalkyl of from 1 to about 10 carbon atoms , cyano, or a group of the formul a R-0-C-(CH 2 ) π - wherein n is an integer from 0 to about 10. When two or more groups of the same designation occur in the same formula, those groups are not necessarily identical. The compounds described herein are not limited to any particular stereoisomeric configuration. In preferred compounds, Y is a straight or branched carbon chain of from 1 to about 5 carbon atoms or aralkyl of from 8 to about 12 carbon atoms. Most preferably, Y is a straight or branched carbon chain of from 1 to about 4 carbon atoms. R is preferably lower alkyl of from 1 to about 5 carbon atoms, lower alkenyl of from 2 to about 5 carbon atoms, lower alkynyl of from 2 to about 5 carbon atoms, aryl of from 6 to about 8 carbon atoms, or aralkyl, wherein the alkyl portion contains from 1 to about 5 carbon atoms and the aryl portion contains from 6 to about 10 carbon atoms. Most preferably, R is lower alkyl of from 1 to about 4 carbon atoms or aralkyl, wherein the alkyl portion contains from 1 to about 4 carbon atoms and the aryl portion contains from β to about 8 carbon atoms. Particul rly preferred R groups are methyl and ethyl. The integer x is preferably 1 or 2; most preferably 1. Ar is preferably unsubstituted aromatic or aromatic substituted with lower alkyl of from 1 to about ' 5 carbon atoms, lower alkenyl of from 2 to about 5 carbon atoms, lower alkynyl of from 2 to about 5 carbon atoms, lower alkoxy of from 1 to about 5 carbon atoms, fluoro, chloro, acetamido, amino, nitro, lower alkylaπino of from 1 to about 5 O PI_ carbon atoms, hydro xy, lower hydroxyalkyl of from 1 to about 5 carbon atoms, cyano, or a group of the formula R-0-C-(CH 2 ) n - wherein n is an integer from 0 to about 5. Ar is more preferably unsubstituted phenyl or phenyl substituted with lower alkyl of from 1 to about 5 carbon atoms, fluoro, chloro, πitro or a group of the formula R-0-C-(CH 2 ) n - wherein n is an integer of from 1 to about 5 and R is lower alkyl of from 1 to about 5 carbon atoms. Most preferably, Ar is 2-alkylphenyl, eg. 2-methyl phenyl. The compounds of this invention may be administered as their pharmaceutically acceptable acid addition salts, e.g., as the hydro-. chloride, sulfate, phosphate, gluconate, tartrate, etc. The compounds of the present invention may be prepared by a number of reaction procedures. The following four reaction schemes have been employed. In all of the reaction schemes, an aryl ether epoxide is used as the starting material. The aryl ether epoxide is prepared from an appropriately derivatized aryl hydroxy compound as follows: Acetone The aryl ether epoxide may then be reacted in the following manner o provide the desired product: OMPI Sc e e I OH 0 Ar-0-CH 2 -CH-CH 2 -NH-Y-C-0-R Scheme II H 0 15 Ar-0-CH 2 Aq . HC1 0 OH Ar-0-CH 2 -CH-CH 2 -NH 2 20 OH 0 Br-Y-C-O-R Ar-0-CH 2 -CH-CH 2 -NH-Y-C-0-R 25 Scheme III OH 30 R-OH Ar-0-CH 2 -CH-CH 2 -NH-Y-C-0H OH 0 Ar-0-CH 2 -CH-CH 2 -NH-Y-C-0-R 35 Scheme IV Ar-0-CH 2 -CH-CH 2 + -CHg-NHg Ar-0-CH 2 - H 2 /Pd-C OH -*} Ar-0-CH 2 -CH-CH 2 -N-Y-C-0-R H The compounds of this invention are advantageously administered " parenterally, e.g., by intravenous injection or intravenous infusion. Formulations for intravenous injection preferably include the active compound as a soluble acid addition salt in a properly buffered isotonic solution. The dosage administered to a patient and the duration of infusion will depend upon the patient's needs and the particular compounds employed. For short periods of infusion, e.g., less than about three hours, the duration of effect is thought to be determined by both metabolic effects and distribution phenomena. For relatively long periods of infusion, e.g., greater than about three hours, the duration of effect is thought to depend largely on metabolic effects. Accordingly, although the present methods and compounds are generally useful for short term infusion therapy, certain compounds are preferred for longer durations of infusion. This principle is demonstrated by referenced to the 40 minute and three hour infusion studies described in Examples LX-LXXIV. The compounds have been found to be generally non- toxic within conventional dosage ranges. Dosages of from about 0.001 to about 100 g. per kg. of body weight per hour are generally employed, with preferred dosages ranging from about 0.01 to about 10 mg. per kg. of body weight per hour. The compounds of the present invention have a relatively short duration of action compared to conventional β-blockers. _In vi tro studies in human whole blood indicate that the ester funcitons are subject to enzymatic cleavage. Compounds of the present invention in which the aromatic portion, Ar, is also substituted with an ester- containing group, have two or more potentially labile sites for enzymatic hydrolysis. Thus β-blocking activity can be carefully con¬ trolled by regulating dosage size and rate of administrat on. The time required for substantially complete disappearance of the β-blockiπg effects of the compounds of the present invention ranges from about 5-10 minutes to about 1 hour or more. Generally, it is preferred that the recovery is accomplished within about 10-15 minutes. A short acting β-blocker can advantageously be infused at a rate sufficient to provide the desired action, e.g., titrated to the specific patient's needs, and such action can be promptly discontinued by stopping the infusion. Thus, the method of the' present invention provides a very useful therapeutic alternative in the treatment or prophylaxis of cardiac disorders. The present invention is furtner illustrated by the following examples which are not intended to be limiting. Example I This example describes procedures producing the following compound: OH 0 0-CH 2 -CH-CH 2 -NH-CH 2 -C-0-CH 2 CH 3 2,3-Epoxy p ropoxybenzene A mixture of 9.4 gm (0.1 mole) of phenol, 28 gm (0.2 mole) of potassium carbonate and 30 mL (0.4 mole) of epichlorohydr n in 250 mL acetone was heated to reflux for 12 hours. The reaction medium was then filtered and evaporated leaving an oil which was taken up in toluene and successively washed with 100 mL water, 2 x 100 mL 1.0 N sodium hydroxide and 2 x 100 L water. The toluene phase was dried with magnesium sulf te and evaporated to provide a clear oil which was chromatographed on a Prep-500 silica gel column employing hexane: ethyl acetate (9:1) as the mobile phase. Collection of the major peak and evaporation of solvent provided 9 gm (60%) of a clear oil whose NMR and IR spectra were consistent with the assigned structure. Ethyl N-(2-Hydroxy-3-phenox . ypropyl ) ql . yciπate Oxalate A solution of 20 gm (0.14 mole) of glycine, ethyl ester hydro- chloride and 40 gm K 2 Co 3 in 100 mL of water was extracted with ether (5 x 100 mL). The ethereal phase was then dried with Na 2 So 4 and evaporated under reduced pressure at a temperature not exceeding 40°C to provide 10.5 gm (71%) of glycine ethyl ester free amine. The glycine ethyl ester free amine (0.10 mole) was used immediately by reacting with 4.0 gm (0.03 mole) of 2,3-epoxypropoxybenzene in refluxing ethanol (50 L). After 4 hours the reaction medium was evaporated under reduced pressure and the resulting oil taken up in 50 L toluene and washed with 4 x 50 L water. The organic phase was dried with MgSO. and evaporated to a yellow oil. An analytical sample of the free amine was obtained by crystal izat ion from ethyl acetate: mp 49-50°. The elemental analysis of this product was consistent with the formula, The major portion of this oil was converted to its oxalate salt and crystalled from ethanol-ether to provide 0.8 gm (8%): mp 144-145°C. The NM-l and IR spectra and elemental analyses conformed to the assigned structure. Example II This example describes the procedures for producing a compound of the formula OH l-Naphthyl-2,3-epoxypropyl Ether The experiment of Example I for preparing 2,3-epoxypropoxybenzene was repeated in all essential details, except that 1-napthol was sub¬ stituted for phenol, and the final product was isolated by vacuum 5 distillation: bp 112-114°C (p=0.25 mm Hg). The Nf<R and IR spectra and elemental analyses conformed to the assigned structure. Ethyl N-[[2-HydrOxy-3-(l-naphtoxy] propyl] qlycinate Oxalate Hemihydrate A mixture of 4.0 gm (0.02 mole) of l-(2,3-epoxypropoxy)- 10 naphtalene, 5.6 gm (0.04 mole) of glycine ethyl ester hydrochloride and 5.5 mL (0.04 mole) triethyl ami ne in 50 mL of ethanol was heated to reflux for 2 hours. The reaction medium was then evaporated under reduced pressure and the resulting oil taken up in 50 mL toluene and washed with 2 x 50 mL water. The organic phase was dried over MgSO, and 15 evaporated under reduced pressure. The resulting oil was crystallized as its oxalate salt from water and provided 1.1 gm (14%) of product: mp 161-162°C. The NMR spectrum was consistent with the assigned structure, and the elemental analysis was consistent with the formula .An anhydrous analytical sample was also obtained by 20 crystal izat ion from acetone: mp 169-170°C. The NM*l spectrum of the analytical sample was also consistent with the assigned structure, and the elemental analysis was consistent with the formula C-, Q H 2 .-N0g. Example III 25. This example describes procedures for producing the following compound: l-Succinimido-3-phenoxy-2-pι-opanol A mixture of 15 gm (0.1 mole) of 2,3-epoxypropoxybenzene (prepared as described in Example I) and 9.9 gm (0.1 mole) of 35 succinimide in 100 L ethanol having 10 drops of pyr dine was heated to reflux for 4 hours. After standing 24 hours at room temperature a white crystalline product separated. This material was collected, air-dried f O H and recrystallized from 700 mL ethyl acetaterhexane (6:1) to give 18 gm (72%) of white crystals: mp 130°. The NM spectrum and the elemental analyses were consistent with the assigned structure. l-Amino-3-pheπoxy-2-propanol Hydrochloride l-Succinimido-3-phenoxy-2-propanol (16 gm, 0.06 mole) was dissolved in 100 mL cone. HC1 and 100 mL ethanol and heated to reflux for 6 hours. After the reaction, the mixture was evaporated to a white residue which was then taken up in 25 mL water and washed with 3 x 50 mL ether. The aqueous phase was then evaporated and the white-residue recrystallized from ethanol to provide 8.3 gm (69%) of white crystals: mp 226-228°. The NMR spectrum was consistent with the assigned structure and the elemental analysis was consistent with the molecular formula C g H 14 N0 2 Cl. Ethyl 3- .N-[2-H,ydroxy-3-pheπoxy) propyl] amino] prooionate Oxalate A mixture of 3.4 gm (0.02 mole) of l-amino-3-phenoxy-2-ρropanol hydrochloride, 2.6 mL (0.02 mole) of ethyl 3-bromopropionate and 2.8 mL (0.02 mole) of triethyl amine in 20 L of ethanol was heated to reflux for 12 hours. The reaction medium was then filtered and evaporated and the residue taken up in 25 mL water/50 L ether. The phases were separated and the ether phase washed twice with 25 mL water. The ethereal phase was then dried with magnesium sulfate and evaporated to provide 1.86 gm of a clear oil. A 1.65 gm (0.0062 mole) portion of this oil in 5 mL ethanol was then added to 0.78 gn (0.0062 mole) of oxalic acid di hydrate in 15 mL ethanol and after standing at room temperature the oxalate salt was produced as a crystalline solid. The material was recrystallized from acetone to provide 1.1 gm (16%) white crystals: mp 137-138 . The NMR spectrum was consistent with the assigned structure and the elemental analysis was consistent with the moecular formula C 16 H 23 N0 8- Example IV This example describes a procedure for preparing a compound of the formula O...PI V.'IPO 0H 0 Ethyl 4-[N-C(2-Hydroxy-3-phenoxy)propyl] aminobutyrate A mixture of 10 gm (0.10 mole) of 4-aπrino utyric acid, 6.6 L of 2,3-epoxypropoxybeπzene (0.05 mole) (prepared as described in Example I) and 4.0 gm (0.10 mole) of NaOH in 160 mL aqueous dioxane (1:3) was heated to reflux for 4 hours. After cooling, 100 mL of water was added and the aequeous medium washed with 400 mL ether. The aqueous phase was acidified to pH 1 by adding concentrated HC1 and then evaporated to a semi-solid residue which was extracted with ethyl acetate. This process removed 5.3 gm (95%) of NaCl side product. Evaporation of ethyl acetate provided the crude amino acid product as an oil which was immediately esterified with 500 L ethanol utilizing a Soxhlet Extractor charged with 250 gm of activated 3A molecular sieves and employing a 96-hour reaction time. Concentration of the ethanol and treatment with ether provide a crystalline material which was sub¬ sequently recrystallized from ethyl acetate to provide 4.1 gm (25%) of product: mp 109-100°C. The MR spectrum was consistent with the assigned structure, and the elemental analysis was consistent with the formula C 15 H 2 N0 4 C1. Example V This example describes the experimental procedures for producing the following compound: OH 0 0-CH 2 -CH-CH 2 - -0-CH 2 -CH 3 Ethyl N[(2-H.ydroxy-3-phenoxy) propyl] tyrosiπate A mixture of 1.4 mL (0.01 mole) of 2,3-epoxypropoxybenzεne (prepared as described in Example I) and 2.1 gm (0.01 mole) in 10 L ethanol was heated to reflux for 4 hours. After the reaction, the mixture was evaporated to a thick clear oil which was than dissolved in 50 L toluene and partitioned with 2 x 40 mL water. The organic phase was then dried with magnesium sulfate and evaporated to an oil. This oil was taken up in 15 L of ethanolic HC1 and treated with 175 mL ether. An oil was gradually produced from this solution after cooling. This oiV was taken up in ethyl acetate and upon evaporation of this solvent, and amorphous solid was obtained: 0.5 gm (14%); mp 60-70°. The NMR spectrum was consistent with the assigned structure and the elemental analysis was consistent with the molecular formula C 2fJ H 26 N0 5 Cl. Example VI This example describes a procedure for preparing a a compound of • the formula OH 0 Ethyl 3[N-[3-[4-chlorophenox . y)-2-hydroxy] oropyl] amino] prooionate Hydrochloride A solution of 9.2 gm (50 mmol) of 4-chloro-l-(2,3-epoxypropoxy) benzene and 5.5 mL (50 mmol) of benzyl ami πe in 125 mL of ethanol was heated to reflux for 4 hours ( a 10 mL aliquot was then treated with concentrated HC1 and ether to provide an analytical sarple of the intermediate secondary benzylamine hydrochloride as a white crystalline product: mp 169-170°C). After cooling the reaction mixture, 6 mL (47 mmol) of ethyl 3-bromopropionate and 6.5 mL (47 mmol) of triethyl amine were added and the mixture heated to reflux for anotyer 10 hours. The reaction medium was then evaporated and the residue taken up in 50 mL toluene - 50 L water. The organic phase was washed an additional two times with 50 mL portions of water and then dried over MgSO, and evaporated to provide the Ethyl 3-[N-benzyl-.\'[3-[(4-chlorophenoxy)-2- hydroxy] propyl] ami no] propionate intermediate as an oil which was characterized by NMR spectroscopy. This oil was used directly in the next reaction by redissolving it in 100 mL of ethanol, adding 7 L (100 πrnol) of acetyl chloride, 100 mg of 10% Pd-C and hydrogenating under 50 psi for 20 minutes. The reaction medium was then filtered and evaporated under reduced pressure to provide the product as an oil which yielded 6.5 gm (41% overall yield) of white crystals from ethanol- ether: mp 119-120°C. The NMR spectrum and elemental analysis were . consistent with the assigned structure. Example VII This example described procedures for preparing a compound of the f ormul a OH 0 0-CH 2 -CH-CH 2 -N-CH 2 -CH 2 -C-0-CH 2 CH 3 CH 3 -0-C-CH 2 -CH 2 Methyl 3(4-H.ydroxyphen,yl )propionate A solution of 300 gm (1.81 mole) of 3-(4-hydroxyphenyl) propiom ' c acid in 1 liter of anhydrous methanol containing 10 drops of con¬ centrated H 2 S0^ was heated to reflux for 72 hours in a Soxhlet Extractor charged with 200 gm of 3A molecular sieves (Linde 3A, 1Λ6 pellets). The reaction medium was then evaporated under reduced pressure and the resulting oil taken up in 750 mL of toluene and washed with three 500 L portions of water. The toluene phase was then dried with MgS0 4 and evaporated under reduced pressure to provide 228.4 gm (70%) of a clear oil which was characterized by NMR spectroscopy and utilized directly in the next step without additional purification. Methyl 3[4-(2»3-Epox.ypropoxy)pheπyl] propionate A mixture of 228 gm (1.27 mole) of methyl 3-(4-hydroxypheπyl)- propionate, 263 gm (1.90 mole) of K 2 C0 3 and 298 L (3.80 mole) of epichlorohydrin in 2 liters of acetone was stirred and heated to reflux for 20 hours. The reaction medium was then filtered and evaporated under reduced pressure. The resulting oil was taken up in 1 liter of toluene and washed consecutively with 500 L water, 2 x 500 mL IN NaOH and 2 x 500 mL water. The toluene phase was then dried over MgSO^ and evaporated under reduced pressure to provide a clear oil which was further purified by vacuum distillation. The final yield of purified oil was 131.2 gm (44%): bp 156° (p=0.4 mm Hg). The NMR and IR spectra of the product were consistent with the assigned structure and the elemental analysis was consistent with the formula C^H-^gO^. Ethyl 3-[N-[2-H . ydroxy-3-[4-[2-(methoxycarboπyl)ethyl]phenoxy] propyl] - amino] propionate Hydrochloride A mixture of 5 gm (0.02 mole of methyl 3-[4-(2,3-epoxypropoxy)- pheπyl] propionate, 3 gm (0.02 mole) of ethyl 3-amiπopropionate hydro¬ chloride and 2.8 ml (0.02 mole) of triethyl amine in 25 L of isopropanol was heated to reflux for 4 hour ' s. The reaction medium was then cooled and the triethyl amine hydrochloride side-product which crystallized was removed by filtration. The mother liquor was then evaporated under reduced pressure and the resulting residue taken up in ethanol and treated with ethereal HC1 to provide 1 gm (12%) as a crystalline solid: mp 110-111°. The NMR spectrum was consistent with ' the assigned structure and the elemental analysis was consistent with the formula C 18 H 28 N0 6 C1. Example VIII This example describes procedures for the prepartion of a com- pound of the formula C-0-CH-, 0 Methyl 2-(2,3-Epoxypropoxy)benzoate The procedure of Example VII for producing methyl 3-[4-(2,3- -epoxypropoxy)phenyl] propionate was repeated in all essential details, except methyl salicylate was substituted for methyl 3-(4-hydroxy- phenyl) propionate. The boiling point of the product was 148° (p=75μ). Th e NMR spectrum was consistent with the assigned structure and the elemental analysis with the formula t ^j -v^ A - Ethyl 3-[N-[2-Hydroxy-3-[2-(methoxycarbonyl)pheπoxy] propyl] amino] - propionate Oxalate Hemi hydrate The procedure for Example VII for producing ethyl 3-[N-[2- hydroxy-3-[4-[2-(methoxycarbonyl)ehtyl]phenoxy] propyl] amino] propionate hydrochloride was repeated in all essential details except methyl 2- (2,3-epoxypropoxy) benzoate was substituted for 3[4-(2,3-epoxy- propoxy) phenyl] propionate and the product was crystallized as its oxlate salt from 2-propanol ether and then recrystallized from acetone. Approximately 2 gm (25%) of product was obtained having a melting point of 90-91°C. The NMR spectrum was consistent with the assigned structure and the elemental analysis was consistent with the formula C 18 H 25 N0 10 .1/2H 2 0. Example IX This example describes the preparation of l-(2,3-epoxypropoxy)- -methyl benzene, which may be used as a starting material for certain compounds described herein. The procedure is representative and may be modified to provide starting material for a variety of compounds. A mixture of 52 mL (0.5 mole) of ortho-cresol, 103 gm (0.75 mole) of K 2 C0 3 and 117 mL (1.5 mole) of epichlorohydrin in 600 mL of acetone was heated to reflux for 16 hours. The reaction medium was then filtered and evaporated under reduced pressure. The resulting oil was taken up in 400 mL of toluene and washed consecutively with 200 mL of water, 2 x 200 L of 1.0 N aq. sodium hydroxide and 200 mL of water. The organic phase was then dried over MgSO^ and evaporated under reduced pressure. The resulting -oil, 54 gm (65%), was utilzied directly in the next step without additional purification. The product was characterized by NMR spectroscopy, and the spectrum was consistent with the assigned struc ¬ ture. Examples X - XX These examples describe the preparation of compounds identified in Table I. The compounds were prepared utilizing the procedure of OM?I Exa ple VI in all essential details, except l-(2,3-epoxypropoxy)-2- methyl benzene was substituted for 4-ch1oro-l-(2,3-epoxypropoxy)benzeπe and the appropriate bromocarboxylic acid ester was substituted for ethyl 3-bromopropionate. Each of the compounds was characterized by NMR spectroscopy and elemental analysis. Table I OH 0 -NH-Y-C-0-R Melting Yi el d Example Y R Salt Point Examples XXI - - XXVI These examples describe the preparation of the compounds identified in Table II. The compounds were prepared utilizing the procedure of Example VI in all essential details, except the appro- priate 2,3-epoxypropoxyaryl compound was substituted for 4-chloro- (2, 3-epoxypropoxy) benzene. Each of the compounds was characterized by NMR spectroscopy and elemental aπaysis. P Table II OH 0 Ar-0-CH 2 -CH-CH 2 -NH-CH 2 -CH 2 -C-0-CH 2 CH 3 Melting Yield Example Ar Salt Point % XXI Oxal te 134-137°C 15 XXIII c ' X Oxal ate 127-128°C 18 XXIV CH 3 0^ Oxal ate 129-132°C 22 XXV CH 3° >- HC1 117-119°C 20 Example XXV 13 [ - XXVIII These examples describe the preparation of the compounds identified in Table III. The compounds were prepared utilizing the procedure of Exanple III in all essential details, except the appro¬ priate bromocarboxylic acid ester was substituted for ehtyl 3-bromo- propionate, and l-(2,3-epαxypropoxy)2-methylbenzene was substituted for 2,3-epoxypropoxybenzeπe. The compounds were identified by NMR spectroscopy and elemental analysis. Table III Melting Yi el d Example Y R Point Salt (%) XXVII -CH 2 - -CH CH- 3 137-138°C Oxal ate 14 XXVIII -CH CH - - {CH 2 ) 2- θ 0CH 3 125-129°C He i- 23 0CH 3 Oxal te Example XXIX The procedure of Example IV was repeated in all essential details to produce a compound of the formula OH 0-CH 2 -CH-CH 2 -NH-CH 2 CH 2 -C-0-CH 3 except l-(2,3 .C-δpoOxypropoxy)naphtalene was substituted for 2,3-epoxy- propoxybenzene, 3-aminopropionic acid was substituted for 4-ami no- butyric acid, and methanol was substituted for ethanol in the esterification step. The product was crystallized in 10% yield as its oxalate salt and had a melting point of 180°C. The NMR spectrum and elemental analysis were consistent with the assigned structure. Example XXX This example describes procedures for the preparation of a compound of the formula OM?I 0 Diethyl 2-Amino-[N-[2-Hydroxy-3-(2-methylpheπoxy)propyl]] propaπedioate Hydrochloride A mixture of lOg (0.061 mole) of 2-methyl-l-(2,3-epoxyproρoxy)- benzene, 12.9 gm 0.061 mole) of diethylaminomalonate hydrochloride and 6.2 gm (0.061 mole) of triethylamine in 100 mL of ethanol was heated to reflux for 24 hours. The reaction medium was then evaporated under reduced pressure and the residue treated with ether. The solid tri¬ ethylamine hydrochloride side product was then removed by filtration. The mother liquor was then treated with HCl gas and provided 2.7 (12%) of white crystals: mp 105-6°. The NMR spectrum was consistent with the assigned structure, and the elemental analysis was consistent with the formula C 17 H 2g C20g. * _. Example XXXI This example describes procedures for the preparation of a com¬ pound of the formula: Diethyl 2-Amino-fN-[2-h.ydrox.y-3-(4-(2-carboπτethoxyethyl)phenoxy- propylll propanedioate Hydrochloride A mixture of 11.8 gm (0.05 mole) of methyl 3-[4-(2,3-epoxy- propoxy) phenyl] propionate, 10.6 gm (0.05 mole) of diethyl 2-aminomalonate hydrochloride and 7 mL (0.05 mole) of diethyl 2- aminomalonate hydrochloride and 7 mL (0.05 mole) of triethylamine in 100 mL of isopropanol was heated to reflux for 4 hours. The reaction O PI medium was then filtered and evaporated under vacuum. The resulting oil was taken up in 100 mL toluene and. washed with 3 x 50 mL water. The organic phase was then dried over MgSQ 4 and evaporated under vacuum. The free amine oil was taken up in ethanol and converted to its hydro- chloride salt by adding ethereal HCl. Approximately 4 gm (20%) of white crystals were obtained: mp 144-145°. The NMR spectrum was consistent with the assinged structure and the elemental analysis was consistent with the formula C^H^NOgCl. Examples XXXII - LIX Several of the compounds of the present invention were tested for β-blockiπg activity in vitro using guinea pig right atria and guinea pig tracheal stips mounted in a tissue bath containing oxgeπated (95% 0<-.-5% 0 C0 2 ) Krebs physiological salt solution at 37 C. Each tissue was sus- pended between a fixed glass rod and a Statham Universal Transducer connected to a Beckman recorder. Atria were allowed to beat spontaneously under a loading tension of approximately 0.5 gm. Intrinsic depressant or stimulant activity was determined for each compound by progessively increasing concentrations in the tissue baths at 60-minute intervals. Tissues were not washed between increments. The maximum concentration showing little or no cardiodepressant activity was chosen for blockade experiments. Changes in rate in response to isoprotereπol were measured in the absnece and presence of test compounds. Spiral strips of guinea pig trachea were suspended under 5 gm resting tension and incubated with phentol amine, tropolone and cocaine. Active tension was generated by additon of carbachol (3.0 x 10 " M) and decreases in tension in response to isoproterenol were quantitated. Cumulative concentration-response curves were produced with isoproterenol both before and after 60 minute incubation of test compounds with atria and trachea. The blocking potency of text compounds was estimated by computing pA 2 values (-log Kg) by the method of Furchgott, The Pharmacological Differentiation of Adrenergic Receptors, Ann. N.Y. Acad. Sci.; 139: 553-570 (1967). Comparison of blockade of right atria! and tracheal responses to isoproterenol permitted assessment of cardioselectivity of test compounds; i.e., cardioselective compouds are relatively more effective in blocking atria! rate than tracheal force responses to isoproterenol. The degree of cardioselectiveity was estimated from the ratio, K g tracheal/K g atria! (io^ A 2 atria -P A 2 tracnea * i ). A ratio greater than one indicates cardioselectivity. Test drugs were dissolved in distilled water and added to the bath (30 mL) in a volume of 10 or 100 uL. The results of the in vitro tests are contained in Table IV. All of the test compounds were active β-blockers. Examples LV - LXXIV The duration of β -blockade was determined _n vivo using pentobartital -anesthetized dogs instrumented for measurement of heart rate using a Beckman cardiotachometεr triggered electronically by a phasic aortic blood pressure signal. Both vagus nerves were severed in the cervical region and the animals were mechanically ventilated. Two experimental designs were used. The first employed a 40-minute infusion of test compound and the second used a 3-hour infusion of test compound. In the 40-minute model, isoproterenol was infused into a foreleg vein at the rate of 0.5 ug/kg/min to induce a β -receptor mediated tachycardia. Various doses of test compound are then infused into a femoral vein over a period of 40 minutes. This infusion was then terminated and recovery from blockade was quantitated. The percent inhibition of the heart rate response to isoproterenol after 40 minutes of infusion of the test compound was computed along with the total cumulative doses received of the 40-minute period. This cumulative dose is expressed as g/kg and is an indication of potency. The time period required for 80% recovery of heart rate respoonse for each dose of test drug was also measured to quaπtitate duration of action. To facilitate comparision of data between animals, the date for potency and duration of action were normalized to a level of 50% inhibition of the isoproterenol response via least squares regression of data from each animal. Test compounds were dissolved in 0.9% NaCl and infused at a rate of 0.05 mL/kg/min or less. In the 3-hours infusion model, bolus doeses of isoproterenol (0.4 ug/kg) were used to assess the degree of β-blockade and recovery from β-blockage after termination of the infusion. The doses were spaced at 10-miπute intervals and were given before, during and following the infusion of test compounds. The infusion rate was adjusted so that at the end of the 3-hour infusion period the degree of isoproterenol inhibition averaged about 50% of control. The results of isoproterenol inhibition averaged about 50% of control. The rεsulsts of the 40-minute infusion are shown in Table V, and the results of the 3-hour infusion are shown in Table VI. Example LXXV - LXXXII These examples describe experiments which demonstrate the disappearance of the compounds of the present invention jji vitro in human whole blood, dog whole blood, and dog liver homogenate. The rate of disappearance of a compound is expressed as the half -life (T, , 2 ), which is the time period in which one-half of the initial amount of compound tested disappears. In each experiment, 1 mL of a solution containing 50 ug of the test compound was added to 1 mL of whole blood or 1 mL of a 33% (w/v) liver homogenate. The samples -were incubated in a Dubnoff shaking metabolic incubator for 2.5, 5.0, 10.0, 20.0, 30.0 and 60.0 minutes at 37°C. At the designated time periods, the test mixtures were removed from the incubator and transferred to a 0°C ice bath. Acetoπitrile (2 mL) was immediately added and the mixtures were mixed to stop enzymatic hyrolysis. Zero time samples we.re . prepared by adding 2 L of acetonrile to denature the proteins prior to addition of the test compounds. After centrifugation to sediment denature proteins, 2 L of the supernatant was removed and analyzed by high pressure liquid chromatography, using a mobile phase of 60% acetontitrile/40% 0.5M sodium phosphate bufer (pH 6.6), a U.V. detector and Waters μ Bondapak Phenyl column. The half life of each test compound was determined graphically by plotting the decrease in concentration as a function of time. The results of the experiments are shown in Table VII. Table IV Test Compound (Numerical Designation Indicates pA- Previous Example Which Describes Example Preparation of Compound) Atria Trachrea Cardioselectivity XXXII I 5.7 5.6 1 XXXIII II 6.2 6.2 1 XXXIV III 7.3 5.9 25 XXXV IV 6.6 6.0 4 XXXVI V inactive inactive XXXVII VI 6.4 5.6 6 XXXVIII VII 5.9 < 5.0 8 XXXIX VIII 6.6 6.6 1.0 XL X 7.5 7.4 1 XLI XI 7.4 6.7 5 XLII XII 7.8 7.4 2.5 XLIII XIII 5.1 - XLIV XIV 5.2 - XLV XV 6.6 5.9 5 XL I XVI 6.9 6.7 1.6 XLV11 XVII 7.5 7.0 1.6 XLVIII XVIII 6.4 XLIX XIX 5.7 L XX 5.7 - LI XXI 7.4 6.6 6 LII XXII 7.4 6.7 5 LIII XXIII 6.7 6.5 1.6 LIV XXIV 6.4 6.7 .5 LV XXV 5.8 4.9 8 Table V Test Compound (Numerical Designation Indicates 80% Previous Example Which Describes Potency Recovery Time No. of Example Preparation of Compound (mq/kg/40 min) (Minutes Experiments LX I very low _, 4 LXI II - 53+11 - LXII II I 12.6+4.1 29+13 4 LXIII IV 16.9+9.1 17+4 3 LXIV XXV 17.2+1.2 11+2 4 LXV X 0.99+0.27 14+2 5 LX I XI 3.1+0.7 15+2 4 1 c LXV11 XI I • 6.8+3.7 11+2 3 I Propranolol 46 Practolol 61 Table VI Test Compound (Numerical Designation Indicates 80% Previous Example Which Describes Potency Recovery Time Nc 1. of Example Preparation of Compound (mq/kq/180 min) %I* (Minutes) Expeiriments LXVIII XVII 4.4 56+2 27+4 4 LXIX VIII 27.4+6.0 53+2 ιo+ 2 5 LXX XXVIII 167.7 85 >60 1 LXXI X 6.8 69+5 >60 3 LXX11 XXII 8.5 77 >60 3 LXXIII XXI 10.9 77 >60 2 LXXIV XVIII 54+14 54+8 >60 3 Propranolol No appreciable recovery after several hours Practolol No appreciable recovery after several hours Table VII '1/2 (Minutes) Example Test Compound* Human Whole Blood Dog Whole Blood Dog Liver Homogenate LXXV XII 93+30 152+71 8.8+6 LXXVI XI 117+39 >180 LXXVII XXII 118+26 40+15 3+3 LXXVI11 XXI 127+50 74+21 4+3 LXXIX XVII 148+2 52+9 9+8 LXXX X 155+9 180+0 3+1 LXXXI XXV 158+8 >180 4+2.5 LXXX11 XV >180 >180 9+6 *Numerical Designation Indicates Previous Example which Describes Preparation of Compound

Claims: CLAI MS 1. A compound of the formula OH Ar-0-CH,-CH-CH,-NH- , t -0-R wherein Y is a straight or branched carbon chain of from 1 to about 10 carbon atoms or aralkyl of from 8 to about 20 carbon atoms; R is lower alkyl, lower alkenyl, lower alkynyl, aryl, or aralkyl; x is an integer from 1 to about 3, provided that when x is greater than 1, different occurrences of the -C00R group may be the same or different; Ar is unsubstituted aromatic or aromatic substituted with lower alkyl, lower alkenyl, loweralkyπyl, lower alkoxy, halogen, acetamido, amino, nitro, lower alkylamino, hydroxy, lower hydroxyalkyl, cyano, or a group of the formula R-0-C-(CH 2 ) n - wherein n is an integer from 0 to about 10; or a pharmaceutical acceptable salt thereof. 2. The compound of Claim 1 wherein R is lower alkyl of from 1 to about 10 carbon atoms, lower alkenyl of from 2 to about 10 carbon atoms, lower alkynyl of from 2 about 10 carbon atoms, aryl of from 6 to about 10 carbon atoms or aralkyl, wherein the alkyl prot on contains from 1 to about 10 carbon atoms and the aryl portion contains from 6 to about 10 carbon atoms. 3. The compound of claim 1, when " en Y is a straight or branched carbon chain of from 1 to about 6 carbon atoms or aralkyl of from 8 to about 12 carbon atoms and R is lower alkyl of from 1 to about 5 carbon atoms, lower alkenyl of from 2 to about 5 carbon atoms, lower alkynyl of from 2 to about 5 carbon atoms, aryl of from 6 to about 10 carbon atoms or aralkyl wherei n the alkyl portion contai ns from 1 to about 5 carbon atoms and the aryl portion contai ns from 6 to about 10 carbon atoms . 4. The compound of cl aim 3 wherei n Ar is unsubstituted aromati c or aromatic substituted with lower alkyl of from 1 to about 5 carbon atoms , l ower al kenyl of from 2 to about 5 carbon atoms, lower al koxy of from 1 to about 5 carbons atoms, fluoro, chloro, acetamido, ami no, nitro, l ower alkyl ami no of from 1 to about 5 carbon atoms, hydroxy, lower hydroxyalkyl of from 1 to about 5 carbon atoms, cyano, or a group of the formul a 0 II R-0-C-(CH 2 ) n - wherein π is an integer from 0 to about 5. 5. The compound of claim 4, wherein Y is a straight or branched carbon chain of from 1 to about 4 carbon atoms and R is lower alkyl of from 1 to about 4 carbon atoms aryl of from 6 to about 8 carbon atoms or aralkyl, wherein the alkyl portion contains from 1 to about 4 carbon atoms and the aryl portion contains from 6 to about 8 carbon atoms, and x is 1 or 2. 6. The compound of claim 5 wherein Ar is unsubstituted phenyl or phenyl substituted with lower alkyl of from 1 to about 5 carbon atoms, fluoro, chloro, nitro or a group of the formula R-0-C-(CH 2 ) n - wherein n is an integer from 1 to about 5, and x is 1. 7. The compound of claim 5 wherein Ar is 2-methylphenyl, and x ^ 1. 8. The compound of claim 7 wherein R is methyl or ethyl 9. The compound of the formula OH wherein R is methyl or ethyl, or a pharmaceutically acceptable salt thereof. 10. The compound of claim 1, 2, 4, 5, 7, 8 or 9 as the hydro¬ chloride, sulfate, phosphate, gluconate or tartrate acid addition salt. 11. A method for the treatment or prophylaxis of cardiac disorders in a mammal, comprising administering to such mammal a short acting β-blocker of the formul wherein Y is a straight or branched carbon chain of from 1 to about 10 carbon atoms or aralkyl of from 8 to about 20 carbon atoms; R is lower alkyl, lower alkenyl lower alkynyl, aryl or aralkyl; x is an integer from 1 to about 3, provided that when x is greater than 1, different occurrances of the -C00R group may be the same or different; Ar is unsubstituted aromatic or aromatic substituted with lower alkyl, lowr alkenyl, lower alkynyl, lowr alkoxy, halogen, acetamido, amino, nitro, lower alkylamino, hydroxy, lower hydro yalkyl, cyano, or a group of the f or ul a R-0-C-(CH 2 ) - wherein n is an integer from 0 to about 10; or a pharmaceutically acceptable salt thereof. 12. The method of claim 11 wherein R is lower alkyl of from 1 to about 10 carbon atoms, lower alkenyl of from 2 to about 10 carbon atoms, lower alkynyl of from 2 to about 10 carbon atoms, aryl of from 6 to about 10 carbon atoms, or aralkyl, wherein the alkyl portion contians from 1 to about 10 carbon atoms and the aryl portion contains from 6 to about 10 carbon atoms. 13. The method of claim 11, wherein Y is a straight or branched carbon chain of from 1 to about 6 carbon atoms or aralkyl of from 8 to about 12 carbon atoms, and R is lower alkyl of from 1 to about 5 carbon atoms-, lower alkeny! of from 2 to about 5 carbon atoms, lower alkynyl of from 2 to about 5 carbon atoms, or aralkyl wherein the alkyl portion contains from 1 to about 5 carbon atoms and the aryl portion contains from 6 to about 10 carbon atoms. 14. The method of claim 13 wherein Ar is unsubstituted aromatic or aromatic substituted with lower alkyl of from 1 to about 5 carbon atoms, lower alkenyl of from 2 to about 5 carbon atoms, lower alkynyl of from 2 to about 5 carbon atoms, lower alkoxy of from 1 to about 5 carbon atoms, fluoro, chloro, acetamido, amino, nitro, lower alkyla ino of from 1 to about 5 carbon atoms, hydroxy, lower hydroxyalkyl of from 1 to about 5 carbon atoms, cyano, or a group of the formula R-0-C-(CH 2 ) n - wherein π is an integer from 0 to about 5. 15. The method of Claim 14, wherein Y is a straight or branched carbon chain of from 1 to about 4 carbon atoms and R is lower alkyl of from 1 to about 4 carbon atoms, aryl, of from 6 to about 8 carbon atoms or aralkyl, wherein the alkyl portions contain from 1 to about 4 carbon atoms and the aryl portion contains from 6 to about 8 carbon atoms, or aralkyl, wherein the alkyl portions contain from 1 to about 4 carbon ato s and the aryl portion contains from 6 to about 8 carbon atoms, and x is 1 or 2. 16. The method of claim 15 wherein Ar is unsubstituted phenyl or phenyl substituted with lower alkyl of from 1 to about 5 carbon atoms, fluoro, chloro, nitro or a group of the formula R-0-C-(CH 2 ) n - wherein n is an integer from 1 to about 5, and x is 1. 17. The method of Claim 15 wherein Ar is 2-methylphenyl 18. The method of claim 17 when " en R is methyl or ethyl. 19. The method of claim 11 wherein the compound is of the formula OH Q wherei n R is methyl or ethyl , or a pharmaceutical ly acceptable sal t thereof. 20. The method of cl aim 11, 12, 14, 15, 17, 18 or 19 wherei n said compound is the hydrochloride, sulfate, phosphate, gluconate or tartrate aci d addition sal t. 21. The method of cl aim 11, 12, 14, 15, 17, 18 or 19 wherei n the compound is admi nistered pareπteral ly. 22. the method of cl aim 21 wherei n the compound is admi nistered by intravenous injection or intravenous i nfusion at a dosage rate of from abut 0.001 to about 100 ms of compound per kg of body weight of said mammal per mg of compound per kg of body weight of said mammal per hour. 23. The method of claim 21 wherein the compound is administered by intravenous injection or intravenous infusion at a dosage rate of from about 0.01 to about 10 mg of compound per kg of body weight of said mammal per hour. 24. A process for preparing a compound of the formula OH 0 Ar-0-CH 2 -CH-CH 2 -N-Y ■ C-O- H wherein Y is a straight or branched carbon chain of from 1 to about 10 carbon atoms or aralkyl of from 8 to about 20 carbon atoms; R is lower alkyl, lower alkenyl lower alkynyl, aryl or aralkyl; x is an integer from 1 to about 3, provided that when x is greater than 1, different occurrances of the -C00R group may be the same or different; Ar is unsubstituted aromatic or aromatic substituted with lower alkyl, lower alkenyl, lower alkynyl, lo r alkoxy, halogen, acetamido, amino, nitro, lower alky!amino, hydroxy, lower hydroxyalkyl, cyano, or a group of the formula R-0-C-(CH 2 ) n - wherein n is an integer from 0 to about 10; or a pharmaceutically acceptable salt thereof; which comprises reacting an aryl hydroxy com¬ pound of the formula ArOH, wherein Ar is defined as hereinbefore, with epichlorohydrin in the presence of a suitable solvent and base at reflux temperature to give an aryl ether epoxide of the formula Ar-O-CH CH-CH wherein Ar is defined as herein before, followed by reacting the aryl ether epoxide according to one of the following methods to give the final product: (a) the aryl either epoxide is reacted with an appropriate amine of the formula H 2 N-Y-C00R, wherein Y and R are defined as herein¬ before, in the presence of an alcohol or other suitable solvent at reflux temperature to give the final product; (b) the aryl ether epoxide is reacted with succinimide by heating the reactaπts to reflux in an alcohol or other suitable solvent foϋowed by reaction of the resulting product with an appropriate acid by heating the reactants to reflux in alcohol or an appro¬ priate solvent to give an amine of the formula OH Ar-0-CH 2 -CH-CH 2 NH 2 which is then reacted with a compound of the formula Br-Y-COOR, wherein Y and R are defined as herein¬ before, by heating the reactants to reflux in an alcohol or other suitable solvent to give the final product; (c) the aryl ether epoxide is reacted with an amino acid of the formula H 2 N-Y-C00H, wherein Y is defined as hereinbefore, by heating the reactants to reflux in an alcohol or other suitable solvent followed by reaction of the product with an alcohol of the formula R-OH, wherein R is defined as hereinbefore, to give the final product; (d) the aryl ether epoxide is reacted with benzylamine by heating the reactants to reflux in an alcohol or other suitable solvent to give a product of the formula Ar-0-CH 2 -CH-CH 2 -NH-CH 2 * y 0 II which is then reacted with a compound of the formula Br-Y-C-O-R by heating the reactants to reflux in the presence of an appropriate alkylamine followed by hydrogeπation of the resulting product to remove the benzyl group and give the final product; and optionally converting the final product of (a), (b), (c), or (d) to a pharmaceutically acceptable salt by reaction with an appro¬ priate acid. 25. The process of claim 24 wherein R is lower alkyl of from 1 to about 10 carbon atoms, lower alkenyl of from 2 to about 10 carbon atoms, lower alkynyl of from 2 about 10 carbon atoms, aryl of from 6 to about 10 carbon atoms or aralkyl, wherein the alkyl protion contains from 1 to about 10 carbon atoms and the aryl portion contains from 6 to about 10 carbon atoms. 26. The process of claim 24, wherein Y is a straight or branched carbon chain of from 1 to about 6 carbon atoms or aralkyl of from 8 to about 12 carbon atoms and R is lower alkyl of from 1 to about 5 carbon atoms, lower alkenyl of from 2 to about 5 carbon atoms, lower alkynyl of from 2 to about 5 carbon atoms, aryl of from 6 to about 10 carbon atoms or aralkyl wherein the alkyl portion contains from 1 to about 5 carbon atoms and the aryl portion contains from 6 to about 10 carbon atoms. 27. The process of claim 26 wherein Ar is unsubstituted aromatic or aromatic substituted with lower alkyl of from 1 to about 5 carbon atoms, lower alkenyl of from 2 to about 5 carbon atoms, lower alkoxy of from 1 to about 5 carbons atoms, fluoro, chloro, acetamido, amino, nitro, lower alkyla ino of from 1 to about 5 carbon atoms, hydroxy, lower hydroxyalkyl of from 1 to about 5 carbon atoms, cyano, or a group of the formula R-0-C-(CH 2 ) n - wherein n is an integer from 0 to about 5. 28. The process of claim 27, wherein Y is a straight or branched carbon chain of from 1 to about 4 carbon atoms and R is lower alkyl of from 1 to about 4 carbon atoms aryl of from 6 to about 8 carbon atoms or aralkyl, wherein the alkyl portion contains from 1 to about 4 carbon atoms and the aryl portion contains from 6 to about 8 carbon atoms, and x is 1 or 2. 29. The process of claim 28 wherein Ar is unsubstituted phenyl or phenyl substituted with lower alkyl of from 1 to about 5 carbon atoms, fluoro, chloro, nitro or a group of the formul R-0-C-(CH 2 } n - wherein n is an integer from 1 to about 5, and x is 1. OMPI rt. VΛto -37- 30. The process of cl aim 28 wherein Ar is 2-methyl phenyl , and x is 1. 31. The process of claim 30 wherein R is methyl or ethyl. 32. The process of claim 24 wherein the compound is of the formula OH II 0 wherein R is methyl or ethyl.

Inventors: BORGMAN ROBERT J, ERHARDT PAUL W, O DONNELL JOHN P
Applicants: AMERICAN HOSPITAL SUPPLY CORP
Application year: 1981
Main classification: C07C121
IPC codes: A61K31, A61P9, A61P25, C07C9, C07C67, C07C227, C07C229, C07C233, C07C253